Nearly $650k awarded to advance potential remyelination drug IFB-048

[DIM]

The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS).

“This grant along with the support from the Society are a testimony to the potential of IFB-048 in multiple sclerosis,” Pierre Miniou, PhD, CEO of Inflectis, said in a company press release.

In MS, inflammation in the brain and spinal cord damages the myelin sheath, a fatty covering that wraps around nerve fibers and helps them send electrical signals, sort of like rubber insulation wrapped around a copper wire. Myelin damage results in nerve signaling dysfunction, which gives rise to the symptoms of MS.

There are more than 20 approved MS treatments, but all of them reduce inflammation. No therapy has ever been proven to actually promote the repair of damaged myelin, called remyelination. Finding new treatments that can promote remyelination is a major goal of modern MS research and the aim of this new project.

Miniou called it “an opportunity to speed up the development of a promising drug candidate, which could constitute a paradigm shift for the benefit of people with MS.”

https://multiplesclerosisnewstoday.com/ ... 8e4xOez0sf